Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: J Biopharm Stat. 2017 Nov 27;28(2):320–332. doi: 10.1080/10543406.2017.1397012

Figure 4.

Figure 4

Simulation results for combining both analytical and PK similarity evidence: (a) ratio of the sample sizes in the Phase 3 study to achieve the power of 80% when the prior evidence is used versus when it is not used; and (b) power of the proposed equivalence test in analyzing the Phase 3 data.